siRNA-based targeting of fractalkine overexpression suppresses inflammation development in a severe acute pancreatitis rat model

International Journal of Molecular Medicine

Volumn 30, Issue 3, 2012, Pages 514-520

  Huang, Liya ^a,b   Ma, Junwen ^a,b   Tang, Yuming ^a   Chen, Ping ^a   Zhang, Shuxian ^a   Zhang, Yongping ^a   Yuan, Yao Zong ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b NINGXIA MEDICAL UNIVERSITY   (China)

Author keywords

AR42J cell; Fractalkine; Inflammation; RNA interference; Sever acute pancreas

Indexed keywords

CERULETIDE; FRACTALKINE; INTERLEUKIN 8; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA;

ACUTE PANCREATITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLONY FORMATION; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE OVEREXPRESSION; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; RAT; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

AMYLASES; ANIMALS; CAERULEIN; CELL LINE; CELL PROLIFERATION; CHEMOKINE CX3CL1; DISEASE MODELS, ANIMAL; GENE EXPRESSION; GENE EXPRESSION REGULATION; INTERLEUKIN-8; LACTATE DEHYDROGENASES; PANCREATITIS, ACUTE NECROTIZING; RATS; RATS, SPRAGUE-DAWLEY; RNA INTERFERENCE; RNA, SMALL INTERFERING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84865181050     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2012.1050     Document Type: Article

References (42)

1. Johnson CD and Abu-Hilal M: Persistent organ failure during the first week as a marker of fatal outcome in acute pancreatitis. Gut 53: 1340-1344, 2004. (Pubitemid 39120123)
2. Takeyama Y: Significance of apoptotic cell death in systemic complications with severe acute pancreatitis. J Gastroenterol 40: 1-10, 2005.
3. Johnson C, Kingsnorth A, Imrie C, et al: Double blind, randomised, placebo controlled study of a platelet activating factor antagonist, lexipafant, in the treatment and prevention of organ failure in predicted severe acute pancreatitis. Gut 48: 62-69, 2001. (Pubitemid 32042643)
4. Mayer J, Rau B, Gansauge F and Beger HG: Inflammatory mediators in human acute pancreatitis: clinical and pathophysiological implications. Gut 47: 546-552, 2000.
5. Umehara H, Bloom ET, Okazaki T, Nagano Y, Yoshie O and Imai T: Fractalkine in vascular biology: from basic research to clinical disease. Arterioscler Thromb Vasc Biol 24: 34-40, 2004. (Pubitemid 38082409)
6. Fong AM, Robinson LA, Steeber DA, et al: Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J Exp Med 188: 1413-1419, 1998. (Pubitemid 28489578)
7. Imai T, Hieshima K, Haskell C, et al: Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 91: 521-530, 1997. (Pubitemid 27508241)
8. Volin MV, Woods JM, Amin MA, Connors MA, Harlow LA and Koch AE: Fractalkine: a novel angiogenic chemokine in rheumatoid arthritis. Am J Pathol 159: 1521-1530, 2001. (Pubitemid 32947980)
9. Lee SJ, Namkoong S, Kim YM, et al: Fractalkine stimulates angiogenesis by activating the Raf-1/MEK/ERK- and PI3K/Akt/eNOS-dependent signal pathways. Am J Physiol Heart Circ Physiol 291: H2836-H2846, 2006. (Pubitemid 44904084)
10. Efsen E, Grappone C, DeFranco RM, et al: Up-regulated expression of fractalkine and its receptor CX3CR1 during liver injury in humans. J Hepatol 37: 39-47, 2002. (Pubitemid 34713053)
11. Segerer S, Hughes E, Hudkins KL, Mack M, Goodpaster T and Alpers CE: Expression of the fractalkine receptor (CX3CR1) in human kidney disease. Kidney Int 62: 488-495, 2002. (Pubitemid 34779759)
12. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K and Tuschl T: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411: 494-498, 2001. (Pubitemid 32494397)
13. Hannon GJ: RNA interference. Nature 418: 244-251, 2002.
14. Duxbury MS, Matros E, Ito H, Zinner MJ, Ashley SW and Whang EE: Systemic siRNA-mediated gene silencing: a new approach to targeted therapy of cancer. Ann Surg 240: 667-674, 2004.
15. Filleur S, Courtin A, Ali S, et al: SiRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth. Cancer Res 63: 3919-3922, 2003. (Pubitemid 36917906)
16. Song E, Lee SK, Wang J, et al: RNA interference targeting Fasprotects mice from fulminant hepatitis. Nat Med 9: 347-351, 2003. (Pubitemid 36362792)
17. Sioud M: Advances in RNA sensing by the immune system: separation of siRNA unwanted effects from RNA inference. Methods Mol Biol 629: 33-52, 2010.
18. Leung RK and Whittaker PA: RNA interference: from gene silencing to gene- specific therapeutics. Pharmacol Ther 107: 222-239, 2005. (Pubitemid 40910042)
19. Kim DH and Rossi JJ: Strategies for silencing human disease using RNA interference. Nat Rev Genet 8: 173-184, 2007.
20. Yulong L, Hong G, Shiaw-Yih L, Goss JA, Brunicardi FC and Li K: siRNA-based targeting of cyclin E over-expression inhibits breast cancer cell growth and suppresses tumor development in breast cancer mouse model. PLoS One 5: e12860, 2010.
21. Yubero S, Ramudo L, Manso MA and De Dios I: Mechanisms of dexamethasone-mediated chemokine down-regulation in mild and severe acute pancreatitis. Biochim Biophys Acta 1792: 1205-1211, 2009.
22. Chen P, Yuan Y, Wang S, Zhan L and Xu J: Captopril, an angiotensin-converting enzyme inhibitor, attenuates the severity of acute pancreatitis in rats by reducing expression of matrix metalloproteinase 9. Tohoku J Exp Med 209: 99-101, 2006.
23. Grewal HP, Mohey el Din A, Gaber L, Kotb M and Gaber AO: Amelioration of the physiologic and biochemical changes of acute pancreatitis using an anti-TNF-alpha polyclonal antibody. Am J Sug 167: 214-218, 1994.
24. Zhang XP, Zhang J, Ma ML, et al: Pathological changes at early stage of multiple organ injury in a rat model of severe acute pancreatitis. Hepatobiliary Pancreat Dis Int 9: 83-87, 2010.
25. Murphy PM: The molecular biology of leukocyte chemoattractant receptors. Annu Rev Immunol 12: 593-633, 1994.
26. Brueckmann M and Borggrefe M: Therapeutic potential of fractalkine: a novel approach to metastatic colon cancer. Gut 56: 314-316, 2007. (Pubitemid 46579755)
27. Inoue A, Hasegawa H, Kohno M, et al: Antagonist of fractalkine (CX3CL1) delays the initiation and ameliorates the progression of lupus nephritis in MRL/lpr mice. Arthritis Rheum 52: 1522-1533, 2005. (Pubitemid 40663944)
28. Cockwell P, Chakravorty SJ, Girdlestone J and Savage CO: Fractalkine expression in human renal inflammation. J Pathol 196: 85-89, 2002.
29. Bjerkeli V, Dama JK, Fevang B, Holter JC, Aukrust P and Froland SS: Increased expression of fractalkine (CX3CL1) and its receptor CX3CR1, in Wegener's granulomatosis-possible role in vascular inflammation. Rheumatology 46: 1422-1427, 2007. (Pubitemid 47317087)
30. Bazan JF, Bacon KB, Hardiman G, et al: A new class of membrane bound chemokine with a CX3C motif. Nature 385: 640-644, 1997.
31. Hundhausen C, Misztela D, Berkhout TA, et al: The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. Blood 102: 1186-1195, 2003. (Pubitemid 36988021)
32. Zhang XP, Wang L and Zhou YF: The pathogenic mechanism of severe acute pancreatitis complicated with renal injury: a review of current knowledge. Dig Dis Sci 53: 297-306, 2008. (Pubitemid 351170009)
33. Kingsnorth A: Role of cytokines and their inhibitors in acute pancreatitis. Gut 40: 1-4, 1997.
34. Al Mofleh IA: Severe acute pancreatitis: pathogenetic aspects and prognostic factors. World J Gastroenterol 14: 675-684, 2008.
35. Brummelkamp TR, Bernards R and Agami R: Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2: 243-247, 2002. (Pubitemid 41043979)
36. Chetty C, Bhoopathi P, Joseph P, Chittivelu S, Rao JS and Lakka S: Adenovirus-mediated siRNA against MMP-2 suppresses tumor growth and lung metastasis in mice. Mol Cancer Ther 5: 2289-2299, 2006. (Pubitemid 44530466)
37. Sandberg AA and Borgstrom A: Early prediction of severity in acute pancreatitis: is this possible? JOP 3: 116-125, 2002.
38. Soutschek J, Akinc A, Bramlage B, et al: Therapeutic silencing of an endogenous gene by systemic administration of siRNAs. Nature 432: 173-178, 2004. (Pubitemid 39545841)
39. Goyal BR, Patel MM, Soni MK and Bhadada SV: Therapeutic opportunities of small interfering RNA. Fundam Clin Pharmacol 23: 367-386, 2009.
40. Sochor M, Richter S, Schmidt A, Hempel S, Hopt UT and Keck T: Inhibition of matrix metalloproteinase-9 with doxycycline reduces pancreatitis-associated lung injury. Digestion 80: 65-73, 2009.
41. Chen C, Xu S, Wang WX, et al: Rosiglitazone attenuates the severity of sodium taurocholate induced acute pancreatitis and pancreatitis-associated lung injury. Arch Med Res 40: 79-88, 2009.
42. Perros F, Drofmuller P, Souza R, et al: Fractalkine-induced smooth muscle cell proliferation in pulmonary hypertension. Eur Respir J 29: 937-943, 2007. (Pubitemid 46711898)